Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014‐04 (Etoile du Nord) trial-Reference-Cited by-同舟云学术

Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014‐04 (Etoile du Nord) trial

Published:2019-06-19 Issue:3 Volume:187 Page:319-327
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Boyle Eileen M.¹^ORCID,Leleu Xavier²,Petillon Marie‐Odile¹,Karlin Lionel³,Doyen Chantal⁴,Demarquette Hélène⁵,Royer Bruno⁶,Macro Margaret⁷,Moreau Philippe⁸^ORCID,Fostier Karel⁹,Marie‐Lorraine Chretien¹⁰,Zarnitsky Charles¹¹,Perrot Aurore¹²,Herbaux Charles¹,Poulain Stephanie¹³¹⁴,Manier Salomon¹,Beauvais David¹,Walker Brian A.¹⁵,Wardell Christopher P.¹⁵,Vincent Laure¹⁶,Frenzel Laurent¹⁷,Caillon Hélène¹⁸^ORCID,Susanna Schraen¹⁹,Dejoie Thomas¹⁸,Avet‐Loiseau Hervé²⁰,Mohty Mohamad²¹,Facon Thierry¹,Arnulf Bertrand,Dib Mamoun,Brechignac‐Bureau Sabine,Godmer Pascal,Tempescul Adrian,Fohrer Cecile,Benboubker Lotfi,Voillat Laurent,Malfuson Jean Valère,Mariette Clara,Tiab Mourad,Rigaudeau Sophie,Jaccard Arnaud,Stoppa Anne‐Marie,Eisenmann Jean‐Claude,Rodon Philippe,Kolb Brigitte,Decaux Olivier,Onraed Brigitte,Attal Michel,Hulin Cyrille,

Affiliation:

1. Department of Haematology Hôpital Claude Huriez, Lille University Hospital LilleFrance

2. Department of Haematology Hôpital de la Miletrie, Poitiers University Hospital Poitiers France

3. Department of Haematology Hôpital Lyon Sud, Lyon University Hospital Pierre‐Bénite France

4. Department of Haematology CHU Dinant Godinne, UCL Namur Yvoir Belgium

5. Department of Haematology Hospitalier Général DunkerqueFrance

6. Department of Haematology Hôpital St Louis ParisFrance

7. Department of Haematology CHRU Cote de Nacre, Caen University Hospital CaenFrance

8. Department of Haematology CHRU Hôtel Dieu, Nantes, University Hospital NantesFrance

9. Department of Haematology UZ Brussel Brussels Belgium

10. Department of Haematology University Hospital DijonFrance

11. Department of Haematology Centre Hospitalier J. Monod, CH du Havre Le HavreFrance

12. Department of Haematology Hôpitaux de Brabois, CHRU Nancy NancyFrance

13. Service d’Hématologie Cellulaire, Centre de Biologie Pathologie Lille University Hospital LilleFrance

14. INSERM UMRS 1172 Lille France

15. Myeloma Centre University of Arkansas for Medical Sciences Little Rock ARUSA

16. Department of Haematology CHU Montpellier MontpellierFrance

17. Department of Clinical Haematology AP‐HP, Necker Hospital ParisFrance

18. Department of Biochemistry University Hospital of Nantes NantesFrance

19. Department of Biochemistry Biology Pathology Centre Lille University Hospital LilleFrance

20. Genomics of Myeloma Unit University Hospital of Toulouse ToulouseFrance

21. Department of Haematology Hôpital Saint Antoine, APHP Paris France

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16059

Reference23 articles.

1. The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology

2. CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH-DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION

3. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

4. CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response

5. CRAN(2018)The Comprehensive R Archive Network. Available at:https://cran.r-project.org/[Accessed July 19 2018].

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant;Cochrane Database of Systematic Reviews;2024-05-02

2. Venous thromboembolism prophylaxis and multiple myeloma patients in real-life: Results of a large survey and clinical guidance recommendations from the IFM group;Thrombosis Research;2024-01

3. Efficacy of isatuximab in combination with steroids for the treatment of relapsed/refractory multiple myeloma patients exhibiting only biochemical progression—A single center retrospective study;European Journal of Haematology;2023-07-24

4. Model‐based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients;CPT: Pharmacometrics & Systems Pharmacology;2023-03-31

5. A Review of Cardiac Amyloidosis: Presentation, Diagnosis, and Treatment;Current Problems in Cardiology;2022-12